



Hi-Affi™ Human Anti-Human KRASG12V/HLA-A*03:01 Complex Monoclonal antibody, clone V2 (DMAB-CDB26096)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	V2 is a TCRm antibody against KRASG12V7–16-HLA-A*03:01. The hydrophobic interactions and an induced conformational change dictate V2 specificity for the KRASG12V peptide.
Specificity	V2 binds to the KRASG12V peptide presented by HLA-A*03:01.
Target	Human KRASG12V/HLA-A*03:01 Complex
Immunogen	Human KRASG12V/HLA-A*03:01 Complex
Isotype	IgG
Source/Host	Human
Species Reactivity	Human
Clone	V2
Purification	>90% determined by SDS-PAGE
Conjugate	Unconjugated
Applications	Suitable for use in SPR, Crystallography, EM. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Format	Liquid
Concentration	lot specific

Size	200 µg, 1 mg
Buffer	PBS (endotoxin < 1EU/mg, lower endotoxin levels may also be offered upon request)
Preservative	None
Storage	Short term at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles.
Ship	Dry ice

BACKGROUND

Introduction	Monoclonal antibodies are at the vanguard of the most promising cancer treatments. Whereas traditional therapeutic antibodies have been limited to extracellular antigens, T cell receptor mimic (TCRm) antibodies can target intracellular antigens presented by cell surface major histocompatibility complex (MHC) proteins. TCRm antibodies can therefore target a repertoire of otherwise undruggable cancer antigens.
Keywords	KRAS; HLA-A; HLA-A3; HLA-A*03:01; HLA-A Complex